Cargando…
Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic
INTRODUCTION: During an influenza epidemic, where early vaccination is crucial, pharmacies may be a resource to increase vaccine distribution reach and capacity. METHODS: We utilized an agent-based model of the US and a clinical and economics outcomes model to simulate the impact of different influe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279616/ https://www.ncbi.nlm.nih.gov/pubmed/30340884 http://dx.doi.org/10.1016/j.vaccine.2018.09.040 |
_version_ | 1783378509496844288 |
---|---|
author | Bartsch, Sarah M. Taitel, Michael S. DePasse, Jay V. Cox, Sarah N. Smith-Ray, Renae L. Wedlock, Patrick Singh, Tanya G. Carr, Susan Siegmund, Sheryl S. Lee, Bruce Y. |
author_facet | Bartsch, Sarah M. Taitel, Michael S. DePasse, Jay V. Cox, Sarah N. Smith-Ray, Renae L. Wedlock, Patrick Singh, Tanya G. Carr, Susan Siegmund, Sheryl S. Lee, Bruce Y. |
author_sort | Bartsch, Sarah M. |
collection | PubMed |
description | INTRODUCTION: During an influenza epidemic, where early vaccination is crucial, pharmacies may be a resource to increase vaccine distribution reach and capacity. METHODS: We utilized an agent-based model of the US and a clinical and economics outcomes model to simulate the impact of different influenza epidemics and the impact of utilizing pharmacies in addition to traditional (hospitals, clinic/physician offices, and urgent care centers) locations for vaccination for the year 2017. RESULTS: For an epidemic with a reproductive rate (R0) of 1.30, adding pharmacies with typical business hours averted 11.9 million symptomatic influenza cases, 23,577 to 94,307 deaths, $1.0 billion in direct (vaccine administration and healthcare) costs, $4.2–44.4 billion in productivity losses, and $5.2–45.3 billion in overall costs (varying with mortality rate). Increasing the epidemic severity (R0 of 1.63), averted 16.0 million symptomatic influenza cases, 35,407 to 141,625 deaths, $1.9 billion in direct costs, $6.0–65.5 billion in productivity losses, and $7.8–67.3 billion in overall costs (varying with mortality rate). Extending pharmacy hours averted up to 16.5 million symptomatic influenza cases, 145,278 deaths, $1.9 billion direct costs, $4.1 billion in productivity loss, and $69.5 billion in overall costs. Adding pharmacies resulted in a cost-benefit of $4.1 to $11.5 billion, varying epidemic severity, mortality rate, pharmacy hours, location vaccination rate, and delay in the availability of the vaccine. CONCLUSIONS: Administering vaccines through pharmacies in addition to traditional locations in the event of an epidemic can increase vaccination coverage, mitigating up to 23.7 million symptomatic influenza cases, providing cost-savings up to $2.8 billion to third-party payers and $99.8 billion to society. Pharmacies should be considered as points of dispensing epidemic vaccines in addition to traditional settings as soon as vaccines become available. |
format | Online Article Text |
id | pubmed-6279616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-62796162019-11-12 Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic Bartsch, Sarah M. Taitel, Michael S. DePasse, Jay V. Cox, Sarah N. Smith-Ray, Renae L. Wedlock, Patrick Singh, Tanya G. Carr, Susan Siegmund, Sheryl S. Lee, Bruce Y. Vaccine Article INTRODUCTION: During an influenza epidemic, where early vaccination is crucial, pharmacies may be a resource to increase vaccine distribution reach and capacity. METHODS: We utilized an agent-based model of the US and a clinical and economics outcomes model to simulate the impact of different influenza epidemics and the impact of utilizing pharmacies in addition to traditional (hospitals, clinic/physician offices, and urgent care centers) locations for vaccination for the year 2017. RESULTS: For an epidemic with a reproductive rate (R0) of 1.30, adding pharmacies with typical business hours averted 11.9 million symptomatic influenza cases, 23,577 to 94,307 deaths, $1.0 billion in direct (vaccine administration and healthcare) costs, $4.2–44.4 billion in productivity losses, and $5.2–45.3 billion in overall costs (varying with mortality rate). Increasing the epidemic severity (R0 of 1.63), averted 16.0 million symptomatic influenza cases, 35,407 to 141,625 deaths, $1.9 billion in direct costs, $6.0–65.5 billion in productivity losses, and $7.8–67.3 billion in overall costs (varying with mortality rate). Extending pharmacy hours averted up to 16.5 million symptomatic influenza cases, 145,278 deaths, $1.9 billion direct costs, $4.1 billion in productivity loss, and $69.5 billion in overall costs. Adding pharmacies resulted in a cost-benefit of $4.1 to $11.5 billion, varying epidemic severity, mortality rate, pharmacy hours, location vaccination rate, and delay in the availability of the vaccine. CONCLUSIONS: Administering vaccines through pharmacies in addition to traditional locations in the event of an epidemic can increase vaccination coverage, mitigating up to 23.7 million symptomatic influenza cases, providing cost-savings up to $2.8 billion to third-party payers and $99.8 billion to society. Pharmacies should be considered as points of dispensing epidemic vaccines in addition to traditional settings as soon as vaccines become available. 2018-10-16 2018-11-12 /pmc/articles/PMC6279616/ /pubmed/30340884 http://dx.doi.org/10.1016/j.vaccine.2018.09.040 Text en This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bartsch, Sarah M. Taitel, Michael S. DePasse, Jay V. Cox, Sarah N. Smith-Ray, Renae L. Wedlock, Patrick Singh, Tanya G. Carr, Susan Siegmund, Sheryl S. Lee, Bruce Y. Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic |
title | Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic |
title_full | Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic |
title_fullStr | Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic |
title_full_unstemmed | Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic |
title_short | Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic |
title_sort | epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279616/ https://www.ncbi.nlm.nih.gov/pubmed/30340884 http://dx.doi.org/10.1016/j.vaccine.2018.09.040 |
work_keys_str_mv | AT bartschsarahm epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT taitelmichaels epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT depassejayv epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT coxsarahn epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT smithrayrenael epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT wedlockpatrick epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT singhtanyag epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT carrsusan epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT siegmundsheryls epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic AT leebrucey epidemiologicandeconomicimpactofpharmaciesasvaccinationlocationsduringaninfluenzaepidemic |